Byong Kim
Direttore/Membro del Consiglio presso LIPELLA PHARMACEUTICALS INC.
Patrimonio netto: 33 440 $ in data 31/05/2024
Posizioni attive di Byong Kim
Società | Posizione | Inizio | Fine |
---|---|---|---|
LIPELLA PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 01/03/2022 | - |
Independent Dir/Board Member | 01/03/2022 | - | |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - |
Storia della carriera di Byong Kim
Precedenti posizioni note di Byong Kim
Società | Posizione | Inizio | Fine |
---|---|---|---|
BRIDGE BIOTHERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/01/2016 | 01/12/2019 |
Corporate Officer/Principal | 01/01/2016 | 01/12/2019 | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - | - |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Investitore di Private Equity | 19/08/2009 | - |
Corporate Officer/Principal | 17/08/2009 | 19/08/2009 |
Formazione di Byong Kim
The University of Texas at Austin | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Carnegie Mellon University | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Israele | 2 |
Corea del Sud | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Settori
Consumer Services | 4 |
Health Technology | 4 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
LIPELLA PHARMACEUTICALS INC. | Health Technology |
BRIDGE BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Technology Services |
- Borsa valori
- Insiders
- Byong Kim
- Esperienza